Home

For healthcare professionals

This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) and the United Kingdom (UK) who are interested in information on VABYSMO®. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.

Faster* and greater*

drying with fewer

injections vs.

aflibercept^1-3

Flexible dosing and
extended durability^1,2,4

Powerful dual-pathway

inhibition^5-8

*Based on post hoc, exploratory analysis with nominal P-value statistical analysis not adjusted for multiple testing (nominal P-value <0.05 vs. aflibercept 2.0 mg Q8W), no formal statistical conclusions can be drawn. Primary endpoint of Phase III studies was non-inferiority in BCVA vs. aflibercept 2.0 mg Q8W for nAMD and DME, and aflibercept 2.0 mg Q4W for RVO.

References

Khanani AM, et al. Ophthalmology. 2024;19:S0161-6420(24)00134-9.
Wong TY, et al. Ophthalmology. 2024;131(6):708-723.
Chaudhary V, et al. Presented at ARVO 2023.
Tadayoni R, et al. Presented at Angiogenesis 2024, presentation available at medically.roche.com.
Regula JT, et al. EMBO Mol Med. 2016;8:1265–88.
Heier JS, et al. Lancet. 2022;399:729–40.
Wykoff CC, et al. Lancet. 2022;399:741–55.
VABYSMO®. SmPC https://go.roche.com/Vabysmo_SmPC Accessed May 2024.

This website contains information on products that is targeted to a wide range of audiences, and may contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in your country of origin.

This website is a global information resource for a public audience, outside of the United States of America and the United Kingdom. This website is produced by Roche and is not intended to provide medical advice and/or treatment guidance. The content on this website is non-promotional and does not make specific reference to the availability or the use of a medicine.

▼ This medicinal product is subject to additional monitoring.